1. |
Yang J, Wang C, Zhao F,et al. Loss of FBP1 facilitates aggressive features of hepatocellular carcinoma cells through the Warburg effect. Carcinogenesis, 2016 Oct 14. pii: bgw109.
|
2. |
Devic S. Warburg effect—a consequence or the cause of carcinogenesis? J Cancer, 2016, 7(7): 817-822.
|
3. |
Warburg O. On the origin of cancer cells. Science, 1956, 123(3191): 309-314.
|
4. |
Fan FT, Shen CS, Tao L,et al. PKM2 regulates hepatocellular carcinoma cell epithelial-mesenchymal transition and migration upon EGFR activation. Asian Pac J Cancer Prev, 2014, 15(5): 1961-1970.
|
5. |
Bhardwaj A, Das S. SIRT6 deacetylates PKM2 to suppress its nuclear localization and oncogenic functions. Proc Natl Acad Sci USA, 2016, 113(5): E538-E547.
|
6. |
Iansante V, Choy PM, Fung SW,et al. PARP14 promotes the Warburg effect in hepatocellular carcinoma by inhibiting JNK1-dependent PKM2 phosphorylation and activation. Nat Commun, 2015, 6: 7882.
|
7. |
Zhang X, He C, He C,et al. Nuclear PKM2 expression predicts poor prognosis in patients with esophageal squamous cell carcinoma. Pathol Res Pract, 2013, 209(8): 510-515.
|
8. |
Zhan C, Shi Y, Lu C,et al. Pyruvate kinase M2 is highly correlated with the differentiation and the prognosis of esophageal squamous cell cancer. Dis Esophagus, 2013, 26(7): 746-753.
|
9. |
Teng Y, Ai Z, Wang Y,et al. Proteomic identification of PKM2 and HSPA5 as potential biomarkers for predicting high-risk endometrial carcinoma. J Obstet Gynaecol Res, 2013, 39(1): 317-325.
|
10. |
郭枫, 陈韵. PKM2 蛋白在胃癌组织中的表达及其预后价值. 临床肿瘤学杂志, 2014, 19(7): 599-602.
|
11. |
Kitamura K, Hatano E, Higashi T,et al. Proliferative activity in hepatocellular carcinoma is closely correlated with glucose metabolism but not angiogenesis. J Hepatol, 2011, 55(4): 846-857.
|
12. |
Dong T, Yan Y, Chai H,et al. Pyruvate kinase M2 affects liver cancer cell behavior through up-regulation of HIF-1α and Bcl-xL in culture. Biomed Pharmacother, 2015, 69: 277-284.
|
13. |
Liu WR, Tian MX, Yang LX,et al. PKM2 promotes metastasis by recruiting myeloid-derived suppressor cells and indicates poor prognosis for hepatocellular carcinoma. Oncotarget, 2015, 6(2): 846-861.
|
14. |
Hu W, Lu SX, Li M,et al. Pyruvate kinase M2 prevents apoptosis via modulating Bim stability and associates with poor outcome in hepatocellular carcinoma. Oncotarget, 2015, 6(9): 6570-6583.
|
15. |
Chen Z, Lu X, Wang Z,et al. Co-expression of PKM2 and TRIM35 predicts survival and recurrence in hepatocellular carcinoma. Oncotarget, 2015, 6(4): 2538-2548.
|